↓ Skip to main content

Dove Medical Press

Article Metrics

The pharmacological cost of COPD during Greek economic crisis

Overview of attention for article published in International Journal of Chronic Obstructive Pulmonary Disease, January 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

policy
1 policy source
twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
24 Mendeley
Title
The pharmacological cost of COPD during Greek economic crisis
Published in
International Journal of Chronic Obstructive Pulmonary Disease, January 2017
DOI 10.2147/copd.s123095
Pubmed ID
Authors

Eirini Stafyla, Theodora Kerenidi, Irini Gerogianni, Mary Geitona, Zoe Daniil, Konstantinos I Gourgoulianis

Abstract

The economic crisis in Greece has substantially affected patients with COPD. The reduction of disposable income has its consequences on patients' ability to afford their medication. The aim of the study is to evaluate the cost of treatment for patients with COPD and the influence of the financial crisis to the patients. Data were collected from 189 patients (male: 178, mean age: 70.1±8.4) who visited the outpatient department of University Hospital of Larissa in 2014 and 2015. The pharmacological cost of treatment was calculated based on national pharmaceutical formulary prices. COPD patients were classified into four stages according to Global Initiative for Chronic Obstructive Lung Disease (GOLD): 7.4% were in stage I, 43.4% in stage II, 34.4% in stage III, and 14.8% in stage IV. Patients were graded as per GOLD as follows: 18% as grade A, 14.3% as B, 23.3% as C, and 44.4% as D. The annual cost of COPD maintenance treatment per patient was €952.92 (±398.01), of which €239.91 were patients' expenses. The annual treatment cost for stable disease ranged from €615.44 to €1302.03 depending on disease stages (GOLD stages I-IV) and from €715.01 to €1101.05 depending on GOLD grades (grades A-D). The cost of maintenance medication was statistically and significantly higher for patients with advanced disease (GOLD stages III-IV) and for patients at high risk (GOLD grades C-D [P=0.000]). The pharmacological cost of treatment for COPD patients seems to be considerably high, in all disease stages. As the average income is decreased, patients face difficulties to afford inhaled medication.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 7 29%
Researcher 4 17%
Other 2 8%
Lecturer 1 4%
Student > Ph. D. Student 1 4%
Other 3 13%
Unknown 6 25%
Readers by discipline Count As %
Medicine and Dentistry 8 33%
Pharmacology, Toxicology and Pharmaceutical Science 4 17%
Nursing and Health Professions 2 8%
Computer Science 1 4%
Business, Management and Accounting 1 4%
Other 2 8%
Unknown 6 25%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2020.
All research outputs
#5,177,719
of 17,549,474 outputs
Outputs from International Journal of Chronic Obstructive Pulmonary Disease
#636
of 1,987 outputs
Outputs of similar age
#116,035
of 366,548 outputs
Outputs of similar age from International Journal of Chronic Obstructive Pulmonary Disease
#33
of 83 outputs
Altmetric has tracked 17,549,474 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 1,987 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.8. This one has gotten more attention than average, scoring higher than 67% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 366,548 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.